Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Revenue
Operating expenses:
General and administrative (including stock-based compensation (Note 8))	320,228	677,890
Depreciation	347	436
Research and development (including stock-based compensation (Note 8))	123,325	169,721
Total operating expenses	443,900	848,047
Loss from operations	(443,900)	(848,047)
Other expense:
Interest expense	117,602	92,496
Total other expense	117,602	92,496
Net loss	(561,502)	(940,543)
Net loss attributable to the noncontrolling interest	505	3,169
Net loss applicable to Bion's common stockholders	$ (560,997)	$ (937,374)
Net loss applicable to Bion's common stockholders per basic and diluted common share (in dollars per share)	$ (0.02)	$ (0.04)
Weighted-average number of common shares outstanding:
Basic and diluted (in shares)	27,466,812	25,659,730